GEN Exclusives

More »

GEN News Highlights

More »
Apr 7, 2011

FDA Sanctions AstraZeneca’s Medullary Thyroid Cancer Drug Vandetanib

  • FDA has approved AstraZeneca’s kinase inhibitor vandetanib for the treatment of unresectable or metastatic medullary thyroid cancer. Clearance was based on data from the Phase III placebo-controlled Zeta trial in 331 patients, which showed that in comparison with placebo, vandetanib therapy boosted progression-free survival from 16.4 months to at least 22.6 months.

    “Vandetanib is the only medicine to receive FDA approval specifically for use in patients with advanced medullary thyroid cancer, and is the first treatment that AstraZeneca has developed and brought to market under orphan drug designation in the U.S.,” notes Howard Hutchinson, AstraZeneca CMO.

    Vandetanib is a VEGFR/EGFR tyrosine kinase inhibitor with RET kinase activity. A regulatory submission in the European Union for the medullary thyroid cancer indication was accepted for review in September 2010. In the U.S., the drug will be launched with a Risk Evaluation and Mitigation Strategy as its use can affect the electrical activity of the heart, AstraZeneca notes.



Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »